Stock Events

Stock Events

Enzymatica

0

0

+SEK0.00+0% 00:00 Today

Statistics

Day High

-

Day Low

-

52W High

-

52W Low

-

Volume

-

Avg. Volume

-

Mkt Cap

0

P/E Ratio

-

Dividend Yield

-

Dividend

-

Upcoming

Earnings

29OctExpected

Q2 2025

Q3 2025

Q4 2025

Next

-0.08

-0.07

-0.06

-0.05

Expected EPS

N/A

Actual EPS

N/A

Financials

-96.27%Profit Margin

Unprofitable

2020

2021

2022

2023

2024

2025

53.9MRevenue

-51.89MNet Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

GlaxoSmithKline, a large pharmaceutical company, competes in the production of various healthcare products, including those for respiratory diseases, potentially overlapping with Enzymatica's cold prevention products.

Johnson & Johnson

Johnson & Johnson offers a broad range of health products, including treatments for respiratory conditions, directly competing with Enzymatica's cold remedies.

Pfizer is involved in the development and manufacturing of healthcare products, including those for respiratory health, competing with Enzymatica's enzyme-based treatments.

Novartis produces healthcare products that address a myriad of conditions, including respiratory diseases, which places them in competition with Enzymatica.

Abbott Laboratories

Abbott Laboratories manufactures medical devices and healthcare products that can compete with Enzymatica's offerings in the general health and wellness sector.

Merck & Co., known for its wide range of pharmaceutical products, competes in the area of respiratory health treatments, relevant to Enzymatica's market.

Roche Holding AG engages in the pharmaceutical and diagnostics business, including areas that overlap with Enzymatica's focus on respiratory and immune health.

Sanofi operates globally in pharmaceuticals, including treatments for respiratory conditions, competing with Enzymatica's product range.

AstraZeneca specializes in several major health areas, including respiratory diseases, making it a competitor to Enzymatica's enzyme-based health products.

About

Enzymatica AB, a life science company headquartered in Lund, Sweden, focuses on the development and sale of medical devices for infection-related illnesses. Founded in 2007, its primary offering is the ColdZyme mouth spray, designed to help prevent and reduce the duration of the common cold. The company also produces various enzyme formulations. This mouth spray is distributed across several European markets under different brand names: ViruProtect in Denmark, STADAProtect in Germany, Psysiomer Stop Virus in France, and Zerinol Virus Defense in Italy.

Show more...

CEO

Sana Alajmovic

Employees

18

Country

Sweden

ISIN

SE0022726394

Listings

0 Comments

Share your thoughts

FAQ

What is Enzymatica stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on Stockholm Exchange exchange Enzymatica stocks are traded under the ticker ENZY-BTA.ST.

When is the next Enzymatica earnings date?▼

Enzymatica is going to release the next earnings report on October 29, 2026.

What were Enzymatica earnings last quarter?▼

ENZY-BTA.ST earnings for the last quarter are -0.05 SEK per share, whereas the estimation was N/A SEK resulting in a N/A surprise. The estimated earnings for the next quarter are N/A SEK per share.

What is Enzymatica revenue for the last year?▼

Enzymatica revenue for the last year amounts to 53.9M SEK.

What is Enzymatica net income for the last year?▼

ENZY-BTA.ST net income for the last year is -51.89M SEK.

How many employees does Enzymatica have?▼

As of September 10, 2026, the company has 18 employees.

In which sector is Enzymatica located?▼

Enzymatica operates in the Health & Wellness sector.

When did Enzymatica complete a stock split?▼

Enzymatica has not had any recent stock splits.

Where is Enzymatica headquartered?▼

Enzymatica is headquartered in Lund, Sweden.